These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27890933)

  • 61. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mechanism of immunomodulatory drug resistance and novel therapeutic strategies in multiple myeloma.
    Zuo X; Liu D
    Hematology; 2022 Dec; 27(1):1110-1121. PubMed ID: 36121114
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.
    Borbely G; Haldosen LA; Dahlman-Wright K; Zhao C
    Oncotarget; 2015 Oct; 6(32):33623-35. PubMed ID: 26378038
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
    Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.
    Gosmini R; Nguyen VL; Toum J; Simon C; Brusq JM; Krysa G; Mirguet O; Riou-Eymard AM; Boursier EV; Trottet L; Bamborough P; Clark H; Chung CW; Cutler L; Demont EH; Kaur R; Lewis AJ; Schilling MB; Soden PE; Taylor S; Walker AL; Walker MD; Prinjha RK; Nicodème E
    J Med Chem; 2014 Oct; 57(19):8111-31. PubMed ID: 25249180
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).
    Zhang M; Zhang Y; Song M; Xue X; Wang J; Wang C; Zhang C; Li C; Xiang Q; Zou L; Wu X; Wu C; Dong B; Xue W; Zhou Y; Chen H; Wu D; Ding K; Xu Y
    J Med Chem; 2018 Apr; 61(7):3037-3058. PubMed ID: 29566488
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The selective activator protein-1 inhibitor T-5224 regulates the IRF4/MYC axis and exerts cooperative antimyeloma activity with bortezomib.
    Tang S; Zhang F; Li J; Dong H; Yang Q; Liu J; Fu Y
    Chem Biol Interact; 2023 Oct; 384():110687. PubMed ID: 37657595
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
    Bennett MJ; Wu Y; Boloor A; Matuszkiewicz J; O'Connell SM; Shi L; Stansfield RK; Del Rosario JR; Veal JM; Hosfield DJ; Xu J; Kaldor SW; Stafford JA; Betancort JM
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1811-1816. PubMed ID: 29657099
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma.
    Welsh SJ; Barwick BG; Meermeier EW; Riggs DL; Shi CX; Zhu YX; Sharik ME; Du MT; Abrego Rocha LD; Garbitt VM; Stein CK; Petit JL; Meurice N; Tafoya Alvarado Y; Fonseca R; Todd KT; Brown S; Hammond ZJ; Cuc NH; Wittenberg C; Herzog C; Roschke AV; Demchenko YN; Chen WD; Li P; Liao W; Leonard WJ; Lonial S; Bahlis NJ; Neri P; Boise LH; Chesi M; Bergsagel PL
    Blood Cancer Discov; 2024 Jan; 5(1):34-55. PubMed ID: 37767768
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.
    Jiménez I; Baruchel A; Doz F; Schulte J
    Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27900832
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A novel cereblon modulator for targeted protein degradation.
    Kim SA; Go A; Jo SH; Park SJ; Jeon YU; Kim JE; Lee HK; Park CH; Lee CO; Park SG; Kim P; Park BC; Cho SY; Kim S; Ha JD; Kim JH; Hwang JY
    Eur J Med Chem; 2019 Mar; 166():65-74. PubMed ID: 30684871
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Non-canonical transcriptional consequences of BET inhibition in cancer.
    Letson C; Padron E
    Pharmacol Res; 2019 Dec; 150():104508. PubMed ID: 31698067
    [TBL] [Abstract][Full Text] [Related]  

  • 74. How to Reprogram Myeloma-Associated Macrophages: Target IKZF1.
    De Sanctis F; Bronte V
    Cancer Immunol Res; 2021 Mar; 9(3):254. PubMed ID: 33648946
    [TBL] [Abstract][Full Text] [Related]  

  • 75. ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma.
    Neri P; Barwick BG; Jung D; Patton JC; Maity R; Tagoug I; Stein CK; Tilmont R; Leblay N; Ahn S; Lee H; Welsh SJ; Riggs DL; Stong N; Flynt E; Thakurta A; Keats JJ; Lonial S; Bergsagel PL; Boise LH; Bahlis NJ
    Blood Cancer Discov; 2024 Jan; 5(1):56-73. PubMed ID: 37934799
    [TBL] [Abstract][Full Text] [Related]  

  • 76. BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations.
    Ma T; Chen Y; Yi ZG; Li YH; Bai J; Li LJ; Zhang LS
    Genes Dis; 2023 Nov; 10(6):2306-2319. PubMed ID: 37554207
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption.
    Mondala PK; Vora AA; Zhou T; Lazzari E; Ladel L; Luo X; Kim Y; Costello C; MacLeod AR; Jamieson CHM; Crews LA
    Cell Stem Cell; 2021 Apr; 28(4):623-636.e9. PubMed ID: 33476575
    [TBL] [Abstract][Full Text] [Related]  

  • 78. BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects.
    Abedin SM; Boddy CS; Munshi HG
    Onco Targets Ther; 2016; 9():5943-5953. PubMed ID: 27729803
    [TBL] [Abstract][Full Text] [Related]  

  • 79. BET bromodomain inhibitors PFI-1 and CPI-203 suppress the development of follicular lymphoma via regulating Wnt/β-catenin signaling.
    Bai M; Huang Y; Suo X; Wang L; Han W; Zhang W
    Heliyon; 2024 Mar; 10(5):e27149. PubMed ID: 38463851
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Transcriptional Plasticity Drives IMiD and p300 Inhibitor Resistance in Multiple Myeloma.
    Yun S; Cleveland JL
    Blood Cancer Discov; 2024 Jan; 5(1):5-7. PubMed ID: 38085608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.